Novel tetramethylpiperidine-substituted phenazines are potent inhibitors of P-glycoprotein activity in a multidrug resistant cancer cell line

Anti-Cancer Drugs

Volumn 8, Issue 7, 1997, Pages 708-713

  Van Rensburg, C E J ^a   Anderson, R ^a   Joone G ^a   Myer, M S ^a   O'Sullivan, J F ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Multidrug resistance; P Glycoprotein; Riminophenazines

Indexed keywords

GLYCOPROTEIN P; PHENAZINE DERIVATIVE; VINBLASTINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; IN VITRO STUDY; LEUKEMIA CELL LINE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CLOFAZIMINE; DRUG RESISTANCE, MULTIPLE; HUMANS; LEUKEMIA; MOLECULAR STRUCTURE; P-GLYCOPROTEIN; PHENAZINES; PIPERIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0030800576     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199708000-00010     Document Type: Article

References (17)

1. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the muiltidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
2. Candell J, Valle V, Soler M. Acute intoxication with verapamil. Chest 1979; 75: 200-1.
3. Sridhar KS, Krishan A, Samy TSA, et al. Prochorperazine as a doxorubicin-effux blocker; phase I clinical and pharmacokinetic studies. Cancer Chemother. Pharmacol. 1993; 31: 423-30.
4. Sonneveld P, Durie BGM, Lokhurst HM, et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 1992; 3: 40255-9
5. Yahanda AM, Adler KM, Fisher GM, et al. Phase 1 trial of etoposide with cyclosporin as a modulator of multidrug resistance. J Clin Oncol 1992; 10: 1624-34.
6. Barry VC, Belton JG, Conalty ML, Denneny JM, Twomey D, Winder F. A new series of phenazines (rimino-compounds) with high anti-tuberculosis activity. Nature 1957; 179: 1013-5.
7. World Health Organization. Wkly Epidem Rep 1987; 62: 101-8.
8. Van Rensburg CEJ, Anderson R, Myer MS, Jooné GK, O'Sullivan JF. The riminophenazine agents clofazimine and B669 reverse acquired multidrug resistance in a human lung cancer cell line. Cancer Lett 1994; 85: 59-63.
9. O'Connor R, O'Sullivan JF, O'Kennedy R. A preliminary investigation of selected antimycobacterial phenazines. Int J Leprosy: in press.
10. Franzblau SG, O'Sullivan JF. Structure-activity relationships of selected phenazines against Mycobacterium leprae in vitro. Antimicrob Agents Chemother 1988; 32: 1583-5.
11. O'Sullivan JF, Franzblau SG, White KE. New clofazimine analogues: a structure activity study in vitro. Health Coop Papers 1992; 12: 191-7.
12. Van Landingham RM, Walker LL, O'Sullivan JF, Shinnick TM. Activity of phenazine analogues against Mycobacterium leprae infections in mice. Int J Leprosy 1993; 61: 406-14
13. Myer MS, Van Rensburg CEJ. Chemosensitizing interactions of clofazimine and B669 with human K562 crythroleukaemia cells with varying levels of expression of P-glycoprotein. Cancer Lett 1996; 99: 73-8.
14. Twentyman PR, Wright KA, Wallace HM. Effects of cyclosporin A and a non-immunosuppressive analogue, O-acetyl cyclosporin A, upon the growth of parent and multidrug resistant human lung cancer cells in vitro. Br J Cancer 1992; 65: 335-40.
15. Ford JM, Hait WN. Pharmacologic circumvention of multidrug resistance. Cytotechnology 1993; 12: 171-212.
16. Savage JE, O'Sullivan JF, Zeis BM, Anderson R. Investigation of the structural properties of dihydrophenazines which contribute to their pro-oxidative interactions with human phagocytes. J Antimicrob Chemother 1989; 23: 691-700.
17. Medlen CE, Anderson R. Patent Application: MDR Treatment. SA 95/1840.